Practice Signal
This review helps pharmacists translate the 2026 lipid guideline changes into concrete lipid clinic workflows across screening, target-based intensification, and nonstatin selection.
The 2026 dyslipidemia guideline restores absolute LDL-C targets and permits non-sequential nonstatin selection while expanding statin eligibility to roughly 87.5 million US adults, so pharmacists should prepare for more shared decision-making, absolute-risk counseling, and earlier use of PCSK9 inhibitors, inclisiran, and bempedoic acid. Since publication, STAREE added the first placebo-controlled outcome data in healthy adults 70 and older (major cardiovascular events HR 0.70, no gain in disability-free survival), and Lp(a)HORIZON missed its primary endpoint, so Lp(a) stays a risk enhancer rather than a treatment target.
Lipid management is shifting from a percentage-reduction, sequential stepladder model toward absolute low-density lipoprotein cholesterol (LDL-C) targets with flexible, non-sequential nonstatin selection. The 2026 American College of Cardiology/American Heart Association (ACC/AHA)/Multisociety dyslipidemia guideline anchors this change, expanding eligibility for primary prevention and formalizing roles for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, and bempedoic acid.
The 2026 ACC/AHA guideline supersedes the 2018 cholesterol guideline by lowering treatment thresholds and adding polygenic risk scores and coronary artery calcium (CAC) scoring for risk refinement. A JAMA analysis (PMID 42475062) quantified the reach: an estimated 87.5 million US adults (56.6%) are now statin eligible for primary prevention, including 21.5 million newly eligible, largely younger and lower-risk individuals. In parallel, the European Atherosclerosis Society (EAS) consensus lowered the age and LDL-C targets for pediatric familial hypercholesterolemia (FH), supporting statin initiation as early as 6 years.
October 2026 update. STAREE (Zoungas et al., NEJM 2026; PMID 42670961) randomized 9,971 adults aged 70 and older without cardiovascular disease, diabetes or dementia to atorvastatin 40 mg or placebo. Over a median 5.9 years, major cardiovascular events fell from 8.3% to 6.0% (HR 0.70; 95% CI 0.61-0.82), while disability-free survival did not change (HR 0.94; 95% CI 0.84-1.05). Serious adverse events were 2.7% in each arm. Separately, Novartis reported on September 4, 2026 that pelacarsen did not reduce cardiovascular death, MI, stroke or urgent coronary revascularization in Lp(a)HORIZON (more than 8,300 patients with established cardiovascular disease and elevated Lp(a)) despite lowering Lp(a). Full results have not yet been presented.
The JAMA eligibility analysis directly operationalizes the 2026 guideline against its 2018 predecessor, confirming a broader treatment-eligible population but not proving clinical benefit in the newly captured lower-risk cohort (mean 10-year atherosclerotic cardiovascular disease (ASCVD) risk 3.1%). The 2025 ACC/AHA/ACEP/NAEMSP/SCAI acute coronary syndrome (ACS) guideline complements the lipid framework on the secondary-prevention side, where very high ASCVD risk patients warrant high-intensity statins (Class I, Level A) plus nonstatin add-on when not at goal (Class IIa, Level B). Tension persists between guideline-driven expansion into low-risk adults and the limited randomized evidence of absolute benefit in that group. For older adults that tension has eased: STAREE supports broad eligibility at 70 and older for cardiovascular endpoints. It also sits beside the 2026 Canadian statin deprescribing guideline for adults 65 and older (PMID 42728062); the two fit if read by patient, since STAREE enrolled community-dwelling adults free of dementia and disability, while deprescribing guidance targets frailty, limited life expectancy and pill burden.
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
2026 ACC/AHA/Multisociety Dyslipidemia Guideline Reframes Lipid Management and Targets
Guideline · Circulation
guideline backbone Supersedes the 2018 guideline and establishes the target-based, non-sequential nonstatin framework with formal roles for PCSK9 inhibitors, inclisiran, bempedoic acid, CAC, and polygenic risk scores.
|
High-intensity statin for very high ASCVD risk, Class I, Level A; nonstatin add-on Class IIa, Level B | Grade: Moderate Practice-changing |
|
2026 Dyslipidemia Guideline Expands Statin Eligibility to Lower-Risk Adults
Study · JAMA
eligibility scale quantification Projects the demographic reach of the 2026 guideline, showing expansion concentrates in younger, lower-risk, and older adults and raising questions about absolute benefit.
|
87.5 million adults (56.6%) statin eligible, including 21.5 million newly eligible (mean 10-year ASCVD risk 3.1%) | Grade: Moderate Confirmatory |
|
EAS Consensus Lowers Age and LDL-C Targets for Pediatric FH
Consensus Statement · European Heart Journal
pediatric extension EAS consensus lowers the age and LDL-C targets for pediatric FH, driving earlier initiation and age-specific nonstatin selection based on cumulative-exposure reduction.
|
Statin initiation as early as 6 years; ezetimibe adds about 15% incremental LDL-C reduction | Grade: Low Practice-changing |
|
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline on ACS Management
Guideline · Circulation
secondary-prevention complement The 2025 ACS guideline anchors the high-risk secondary-prevention context in which aggressive statin-plus-nonstatin lipid lowering is applied.
|
Ticagrelor preferred over prasugrel for NSTE-ACS, Class I, Level B; colchicine Class IIa, Level B | Grade: Moderate Practice-changing |
|
STAREE: Atorvastatin Cuts Cardiovascular Events but Not Disability in Elders
Study · New England Journal of Medicine
older-adult primary prevention RCT First large placebo-controlled statin outcome trial in adults 70+ without CVD, diabetes or dementia: fewer cardiovascular events, no gain in disability-free survival.
|
Major cardiovascular events 6.0% vs 8.3% (HR 0.70, 95% CI 0.61-0.82); disability-free survival HR 0.94 (0.84-1.05) | Grade: High Practice-changing |